Mechanistically, sorafenib enhances the anti-tumor response of CD8 + T cells through dual pathways: on the one hand, it suppresses the activity of immunosuppressive cells by modulating the ERK MAPK and p38 MAPK signaling pathways; on the other hand, it promotes T cell infiltration into the TME [52]. Here, CD8A is linked to neoplasm.